SecBot SecBot
COURT-RULING ·Filed Aug 19, 2026

TXG

10x Genomics, Inc.
BEARISH
Impact 7/10
Horizonweeks Processed2mo ago CourtCourt Ruling · govinfo.gov
Actionable Insight ▼ Bearish

This ruling removes a key IP barrier for competitors like Parse Biosciences, potentially accelerating market share erosion for 10x's core single-cell analysis products. Traders should monitor for any subsequent competitor product launches or licensing deals that exploit the invalidated patents, and watch for 10x's next quarterly report for any impact on revenue growth or market share commentary.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$63.87
T+0 close · Aug 20, 2026 · via day close
Latest settled
−8.89%
T+60 · $58.19
Vs SPY
−7.81%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 20 $63.87entry
  2. T+1 · 3mo ago +1.97%α +1.56% · $65.12
  3. T+5 · 3mo ago +1.54%α +0.43% · $64.85
  4. T+20 · 2mo ago +19.94%α +20.06% · $76.60
  5. T+60 · 4d ago −8.89%α −7.81% · $58.19
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The Federal Circuit affirmed PTAB decisions invalidating all claims of three 10x Genomics patents (’981, ’197, ’013) as obvious in IPRs brought by Parse Biosciences. This is a significant loss for 10x Genomics' patent portfolio covering core single-cell analysis methods, weakening its competitive moat and potentially exposing it to increased competition from Parse and other rivals. The ruling is final and nonprecedential but represents a material erosion of 10x's IP barriers in its key market.

Court Ruling Details

Ruling Date
Aug 19, 2026
Court
United States Court of Appeals for the Federal Circuit
Court Level
Appellate
Judge
Cunningham
Case Type
patent
Ruling Type
final judgment
Outcome
LOSS: ruling against this company
Precedent Risk
MEDIUM

Key Facts

  • Federal Circuit affirmed PTAB decisions that all claims of U.S. Patent Nos. 10,155,981, 10,240,197, and 10,697,013 are unpatentable as obvious.
  • The three patents cover methods for analyzing nucleic acids from single cells, a core technology for 10x Genomics.
  • The court rejected all four of 10x's challenges to the Board's motivation-to-combine and disclosure findings.
  • The ruling is a final, nonprecedential disposition from the Federal Circuit, with no further appeal within the patent office.
  • The IPRs were brought by competitor Parse Biosciences, which directly competes with 10x in single-cell analysis.

Financial Impact

Loss of patent protection on core single-cell analysis methods; no damages awarded as this is a patent invalidity ruling. The financial impact is the erosion of competitive barriers protecting 10x's revenue from single-cell products.

competitive_positionintellectual_property_moat

Risk Factors

  • Increased competition from Parse Biosciences and other single-cell analysis companies now able to operate without infringement risk from these patents.
  • Potential loss of licensing revenue if 10x had been licensing these patents to others.
  • Possible negative sentiment on 10x's overall patent portfolio strength, potentially affecting partner/customer confidence.

Market Snapshot

Exchange
Nasdaq
Sector
Laboratory Analytical Instruments
Analyst Consensus
45% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 court opinions.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-41ce2165bb-TXG
COURT-RULING Data (Synthetic)court-3f0f4d9a7b-TXG
COURT-RULING Data (Synthetic)court-ce52c07577-TXG

Track record

28 reports on TXG

Performance horizon

0 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +0.90% at T+1 after the Sep 3, 2026 report. 1 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $55.40 Now $54.99 −0.74% settles Feb 12
  2. Nov 6, 202610d ago 3 Neutral 1/10 Entry $65.05 Now $54.99 −15.47% settles Feb 5
  3. Nov 6, 202610d ago 3 Neutral 1/10 Entry $65.05 Now $54.99 −15.47% settles Feb 5
  4. Nov 5, 202611d ago 8-K Bullish 6/10 No price data
  5. Nov 5, 202611d ago Press Release Mixed 5/10 Entry $59.28 Now $54.99 −7.24% settles Feb 4
  6. Nov 2, 202614d ago 8-K Neutral 2/10 Entry $65.29 Now $54.99 −15.78% settles Feb 1
  7. Oct 23, 202624d ago Institutional Cluster Neutral 2/10 Entry $71.55 Now $54.99 −23.14% settles Jan 21
  8. Oct 7, 20265w ago SC 13G/A Neutral 2/10 Entry $77.28 Now $54.99 −28.84% settles Jan 5
  9. Sep 24, 20267w ago Insider Cluster Neutral 3/10 Entry $85.71 Now $54.99 −35.84% settles Dec 21
  10. Sep 22, 20267w ago 144 Neutral 2/10 Entry $75.62 Now $54.99 −27.28% settles Dec 17
Showing 10 of 28

US Market Status

Market Closed · Opens Wed (9h 57m)

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ Court Ruling · govinfo.gov Report published Aug 20, 2026